Pay for Delay’ Pharmaceutical Settlements and the ‘Quick Look’ – What Does It All Mean?

The “quick look” approach to antitrust analysis has come into heightened focus with the recent oral arguments before the U.S. Supreme Court in the government’s challenge to pay-for-delay settlements between brand-name drug manufacturers and generic-drug manufacturers. In Federal Trade Commission v. Actavis Inc., the government urged the court to adopt a “quick look” form of antitrust scrutiny. In "Pay-for-delay pharmaceuticals settlements and the ‘quick look,’ what does it all mean?," published in the June issue of Westlaw Journal Antitrust, Jeffery M. Cross provides insight into the "quick look" approach.

Available Downloads